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INTRODUCTION
Pancreaticopleural  fistula  is  a  rare  complication  of  acute 
and  chronic  pancreatitis  caused  by  an  inflammatory  or 
traumatic injury to the pancreatic duct. The ensuing thoracic 
collections may be in the form of pleural effusions, pleural 
pseudocysts or mediastinal pseudocysts. Treatment options 
may be conservative or surgical. We present a case of post 
endoscopic  retrograde  cholangio-pancreatography  (ERCP) 
acute  pancreatitis  with  a  pancreaticopleural  fistula  where 
conservative management failed.
CASE REPORT
A 51 year old lady presented with dyspnoea, cough, chest 
pain  and  a  pleural  effusion  two  months  after  recovering 
from an episode of ERCP- induced pancreatitis. A CT scan 
revealed pancreatic necrosis and bilateral pleural effusions. 
Bilateral chest drains were inserted and the amylase content 
of the pleural fluid was elevated at 5488 IU. The presence of 
a pancreaticopleural fistula was considered as a differential 
diagnosis.  She  developed  multiorgan  failure  requiring 
ventilation, inotropic support and renal dialysis. A repeat CT 
scan (fig.1) revealed a pancreatic pseudocyst (7 x 2 cm), a 
mediastinal fluid collection, partial collapse of the left lung 
and bilateral pleural effusions (fig.2). Magnetic resonance 
cholangio-pancreatography  (MRCP)  suggested  a  fluid 
containing tract extending from the pancreas into the chest, 
associated with a collection in the left pleural cavity. 
She  initially  improved  clinically  with  supportive  and 
conservative  measures  but  deteriorated  again  and 
surgical drainage of the pseudocyst was undertaken via a 
cystgastrostomy. At operation a communicating tract leading 
superiorly  through  the  oesophageal  hiatus  was  identified. 
The wall of the cavity was sutured to the posterior wall of the 
stomach and a nasogastric tube was placed into the pseudocyst 
cavity to allow it to collapse and fibrose. Parenteral nutrition 
was commenced post-operatively. The pseudocyst and pleural 
effusions resolved. She was discharged on day 12 and remains 
asymptomatic with no evidence of recurrence after four years.
Fig 1. CT of abdomen demonstrating 7x2cm pancreatic pseudocyst 
(outlined arrow) and dilated pancreatic duct (black arrow). 
Incidental finding of cyst in VI liver lobe (white arrow) is noted.
Fig 2. CT scan of chest demonstrating collapse of the left lung and 
effusions in the left pleural cavity (arrows).© The Ulster Medical Society, 2009.
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DISCUSSION
Pancreaticopleural fistula is an uncommon complication of 
both acute and chronic pancreatitis and pancreatic trauma 
with  duct  disruption.    The  majority  of  cases  (80%)  are 
associated with alcohol induced chronic pancreatitis1-3. There 
is an incidence of 0.4% in patients presenting with pancreatitis 
and 4.5% in those presenting with a pancreatic pseudocyst3. 
The pathogenesis involves recurrent, chronic inflammation 
of the gland eventually leading to ductal disruption. If this 
occurs posteriorly pancreatic secretions will tract through 
the retroperitoneal space via the path of least resistance to 
the pleural cavity4,5. Fistulization through the oesophageal 
or aortic hiatus is most frequent, although extension directly 
through diaphragmatic muscle has been reported6. Conversely, 
anterior ductal disruption is responsible for pancreatic ascites. 
Clinical presentation is often misleading, as symptoms are 
usually associated with a significant pleural effusion, and 
consist of dyspnoea, cough and chest pain. Rarely do patients 
complain of abdominal pains typical of pancreatitis3,7. In one 
study only 52% of patients had a prior history of pancreatitis 
highlighting  that  a  pancreaticopleural  fistula  may  be  the 
first presentation of significant pancreatic disease3. Pleural 
effusions of this nature tend to be large and recurrent despite 
repeated thoracocentesis. Frequently, the diagnosis is delayed 
and it is therefore of vital importance to have a high index of 
suspicion, enquire about excess alcohol consumption, assess 
nutritional status, and examine for the presence of ascites.
Pleural effusions associated with pancreaticopleural fistulae 
should be distinguished from the small, reactive, self-limiting 
left-sided effusions that commonly occur in 3-17% of patients 
with acute pancreatitis8. A pancreaticopleural fistula may be 
suspected on the basis of the clinical picture and an extremely 
elevated pleural fluid amylase level (normal range <150 IU/L) 
following  thoracocentesis.  Importantly,  however,  pleural 
fluid  amylase  may  also  be  elevated  in  acute  pancreatitis 
(<4000 IU/L), oesophageal perforation and certain neoplastic 
processes including lung adenocarcinoma, lymphoma and 
ovarian, rectal, cervical, breast and pancreatic carcinoma2. 
The pleural effusions are predominantly left sided, however 
right sided and bilateral effusions occur in 19% and 14% of 
patients respectively. Simple chest radiography is the first 
line investigation but this provides only limited information 
about the fluid collection in pleural cavity. Currently, the gold 
standard for investigating pleural effusions is CT. It is very 
useful in determining the site and size of the effusion but 
overall ability to provide accurate delineation of the fistula is 
disputable2,8. MCRP and ERCP are also available to visualise 
the biliary tree and pancreatic duct. The latter is less sensitive 
but offers the therapeutic option of stent insertion1,2. 
Currently  there  are  no  systematic  studies  evaluating 
the  optimal  management  of  pancreaticopleural  fistulae 
and  current  methods  derive  from  case  reports  and  small 
case  series1.    Initial  management  should  be  directed  at 
achieving  symptomatic  control  of  the  pleural  effusion, 
with thoracocentesis and chest drain insertion if required. 
Suppression of pancreatic exocrine secretions by somatostatin 
or its analogue octreotide should then be considered.  In 
one  study  a  combination  of  thoracocentesis,  octreotide 
analogues and TPN resulted in a 48% closure rate after three 
weeks9. Surgical treatment, however, is safe and effective 
and  is  appropriate  either  when  medical  management 
fails  or  where  the  underlying  condition  requires  surgical 
intervention.  Cystgastrostomy,  cystjejenostomy,  and  distal 
or middle segment pancreatectomy are appropriate options 
in  the  setting  of  symptomatic  pancreatic  pseudocysts  or 
pancreatic duct obstruction. Finally, ERCP and pancreatic 
duct stenting is a less invasive alternative to surgery. Fistulae 
are unlikely to heal with medical measures alone if drainage 
is impaired by a pseudocyst or stricture. A pancreatic stent 
that bridges the ductal disruption facilitates closure of the 
fistula  by  decreasing  ductal  pressure  and  occluding  the 
luminal  defect1.  Sphincterotomy  and  non-bridging  stents 
have also been reported as being successful but overall a 
significant  proportion  of  patients  undergoing  ERCP  still 
ultimately require surgical intervention1. In one study, 7 of 
18 cases managed endoscopically eventually required surgical 
intervention and even advocates of ERCP acknowledge that 
the issue of how long to persist with this form of treatment 
is, as yet, unresolved1,10.
CONCLUSION
Pancreaticopleural  fistulae  are  difficult  to  diagnose  and 
require a high index of suspicion, particularly in the setting 
of recurrent pleural effusions with a coexisting history of 
pancreatitis  or  alcohol  abuse.  Early  pleural  fluid  amylase 
testing will avoid a delayed diagnosis. First line treatment 
includes drainage of the effusion, inhibition of pancreatic 
secretions with octreotide and possibly ERCP plus stenting 
of the pancreatic duct. As demonstrated by this case, surgery 
is appropriate when medical measures fail or if there is an 
associated symptomatic or complicated pseudocyst.
The authors have no conflict of interest.
REFERENCES
1.   Dhebri AR, Ferran N. Nonsurgical management of pancreaticopleural 
fistula. JOP  2005;6(2):152-61. Available online from: http://www.
joplink.net/prev/200503/13.html Last accessed June 2009.
2.   Rockey DC, Cello JP. Pancreaticopleural fistula. Report of 7 patients 
and review of the literature. Medicine (Baltimore) 1990;69(6):332-44.
3.   Fulcher AS, Capps GW, Turner MA. Thoracopancreatic fistula: clinical 
and imaging findings. J Comput Assist Tomogr 1999;23(2):181-7.
4.   Cameron  JL,  Kieffer  RS,  Anderson  WJ,  Zuidema  GD.  Internal 
pancreatic fistulas: pancreatic ascites and pleural effusions. Ann Surg 
1976;184(5):587-93.
5.   Lipsett  PA,  Cameron  JL.  Internal  pancreatic  fistula.  Am  J  Surg 
1992;163(2):216-20.
6.   Bedingfield  JA, Anderson  MC.  Pancreatopleural  fistula.  Pancreas 
1986;1(3):283-90.
7.   Shibasaki S,  Yamaguchi H, Nanashima A, Tsuji T, Jibiki M, Sawai T, et al. 
Surgical treatment for right pleural effusion caused by pancreaticopleural 
fistula. Hepatogastroenterol 2003;50(53):1678-80.
8.   Wakefield  S,  Tutty  B,  Britton  J.  Pancreaticopleural  fistula:  a  rare 
complication of chronic pancreatitis. Postgrad Med J 1996;72(884):115-
6.
9.   Cameron JL. Chronic pancreatic ascites and pancreatic pleural effusion. 
Gastroenterol 1978;74(1):134-40.
10.   Neher JR, Brady PG, Pinkas H, Ramos M. Pancreaticopleural fistula in 
chronic pancreatitis: resolution with endoscopic therapy. Gastrointest 
Endosc 2000; 52(3): 416-8.